Mike Zaccardi upgraded the iShares MSCI Europe Financials ETF (EUFN) to a buy rating, highlighting its attractive valuation at 8.8 times earnings and a PEG ratio below 1.0 due to an 11% recent price drop. Despite risks from Eurozone fiscal issues, the ETF shows strong technical support at its 200-day moving average and promising seasonal trends. Nearly half of its portfolio is concentrated in the top 10 holdings, and it offers a 4.31% yield, appealing to income-focused investors. This upgrade comes as Q3 bank earnings season begins amid pressure on both US and European financial stocks.
The iShares MSCI Europe Financials ETF (EUFN) offers a 4.31% dividend yield and trades at 8.8 times earnings, with a PEG ratio below 1.0 as of October 12, 2026. For readers following financial stocks, here is Pluang's market snapshot as of Oct 12, 2026 02:41 WIB: of 118 priced Financials-sector US stocks tradable on Pluang, 59 rose and 58 fell today. Notable movers include FIGR at USD 28.54 (+3.41%), ITUB at USD 10.16 (+3.36%), and WU at USD 6.12 (-3.32%).
Acoramidis, a drug for transthyretin amyloid cardiomyopathy (ATTR-CM), was linked to an 18% lower risk of death, hospitalization, and disease progression compared to tafamidis in a large U.S. electronic health record study of 2,684 patients. The stud...
Stellantis revealed six concept cars from its iconic brands at an exclusive event before the Paris Motor Show, highlighting its FaSTLAne 2030 strategy focused on innovation, customer experience, and diverse mobility solutions. These concepts, includi...
Freenome announced improved clinical validation results for its updated SimpleScreen™ CRC blood test, showing an 18.2% sensitivity for advanced precancerous lesions (APLs), up from 13.7% in the original test. Sensitivity for high-grade dysplasia APLs...
BridgeBio Pharma announced that encaleret, a treatment for autosomal dominant hypocalcemia type 1 (ADH1), increased bone turnover and improved patient-reported symptoms in the Phase 3 CALIBRATE trial. 100% of patients on encaleret reported symptom im...
Bitcoin appears to have entered a new bull market as it recovered above its 50-week moving average, a key technical signal seen in past bull runs. Despite recent market dips and liquidations, indicators like the MVRV ratio suggest improving market st...
